Actively Recruiting
Proteomic Pattern Associated With the Diagnosis of Chronic Thromboembolic Pulmonary Hypertension : PROTEO-CTEPH Study.
Led by Centre Hospitalier Universitaire de Saint Etienne · Updated on 2025-11-24
120
Participants Needed
1
Research Sites
47 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Chronic ThromboEmbolic Pulmonary Hypertension (CTEPH) is a rare but serious condition that can develop after a pulmonary embolism (PE). It causes ongoing shortness of breath and is suspected when patients have lung scan perfusion defects and signs of pulmonary hypertension (PH) on transthoracic echocardiography (TTE). This research aims to find a specific proteomic pattern in patients suspected of having CTEPH to improve diagnosis accuracy, as TTE alone may not be sufficient. Participants suspected of CTEPH will undergo standard right heart catheterization and give a blood sample for proteomic analysis at the start. For those confirmed with CTEPH, a second blood sample will be taken six months later. This study is observational and focuses on collecting data without experimental treatment interventions. Participants will be evaluated through lung scans, echocardiography, and right heart catheterization to confirm or rule out CTEPH. Blood samples will be analyzed for proteomic patterns at diagnosis and, if confirmed, again after six months. Researchers will also review hemodynamic data at diagnosis and follow-up. The study is expected to continue through May 2027, with participants monitored and data collected at these key points.
CONDITIONS
Brief Title
Proteomic Pattern Associated With the Diagnosis of Chronic Thromboembolic Pulmonary Hypertension
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patient with a suspicion of Chronic thromboembolic pulmonary hypertension (CTEPH) based on a combination of perfusion lung scan and transthoracic echocardiography compatible with the diagnosis according to French recommendations
- Patients who require a right heart catheterization
- Patient affiliated or entitled to a social security plan
- Patient having received informed information about the study
You will not qualify if you...
- Patient with a normal perfusion lung scan
- Person under legal guardianship
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 1 day
Participants undergo right heart catheterization and blood sample collection to confirm diagnosis of Chronic ThromboEmbolic Pulmonary Hypertension (CTEPH).
1 visit (in-person)
Duration - 6 months
Participants with confirmed diagnosis provide a follow-up blood sample and undergo hemodynamic data analysis at 6 months to monitor disease progression and treatment effects.
1 follow-up visit at 6 months
Trial Site Locations
Total: 1 location
1
CHU de SAINT-ETIENNE
Saint-Etienne, France, 42055
Actively Recruiting
Research Team
L
Laurent BERTOLETTI, MD PhD
C
Carine LABRUYERE
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
1
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here